Form 4: Kezar Life Sciences Director Michael Kauffman Granted 5,000 Stock Options

Kezar Life Sciences, Inc. disclosed that Director Michael Kauffman was granted 5,000 stock options with an exercise price of $4.46, vesting in June 2026.

Summary

• Michael Kauffman, a Director of Kezar Life Sciences, Inc. (KZR), was granted 5,000 stock options.
• The options have an exercise price of $4.46 per share.
• The transaction date for the option grant was June 18, 2025.
• The options will vest 100% on June 18, 2026, contingent upon Mr. Kauffman's continued service.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Kauffman beneficially owns 5,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders and indicates continued commitment, which is generally viewed favorably by the market.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and commitment to the company.
• The vesting schedule encourages the director's continued service to the company.

Future Outlook

The vesting schedule of the stock options on June 18, 2026, implies an expectation of Michael Kauffman's continued service as a director through that date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and life sciences industry, serving as a key component of executive and director compensation packages to attract and retain talent, and to align their financial interests with the long-term success of the company.

Related Party Transactions

• Michael Kauffman, a Director of Kezar Life Sciences, Inc., was granted 5,000 stock options by the company, representing a compensation-related transaction between a related party and the issuer.

Stakeholder Impact

• Shareholders: The grant of options can align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence employee morale and retention.

Next Steps

• The stock options are scheduled to vest on June 18, 2026, provided the reporting person continues to provide service.

Key Dates

Keywords

Kezar Life Sciences, KZR, Stock Option, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Biotechnology